학술논문
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Document Type
Article
Author
Source
In The Lancet Oncology June 2017 18(6):732-742
Subject
Language
ISSN
1470-2045